Agios Pharmaceuticals vs Altimmune
Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Altimmune's grew 105.0%. Agios Pharmaceuticals had an operating margin of -873.9%, against -230461.0% at Altimmune. Free cash flow was −$377 million at Agios Pharmaceuticals and −$68 million at Altimmune.
Side by side
| Agios Pharmaceuticals | Altimmune | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $54M | $0M |
| Revenue growth | 48.0% | 105.0% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 88.3% | — |
| Operating margin | −873.9% | −230,461.0% |
| Net margin | −764.0% | −214,861.0% |
| Free cash flow | −$377M | −$68M |
| Free cash flow margin | −698.3% | −164,746.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.1% | 24.1% |
| Last close | $31.59 | $1.65 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $4.3 million | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Agios PharmaceuticalsAltimmune
Operating margin
Percent of revenue
Agios PharmaceuticalsAltimmune
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsAltimmune
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Altimmune pages.